In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Biolase (BIOL – Research Report), with a price target of $5.00. The company’s shares opened today at $0.50.
According to TipRanks, Vendetti is a 2-star analyst with an average return of 0.4% and a 33.40% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Icecure Medical, Biolase, and Cutera.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biolase with a $5.00 average price target.
See today’s best-performing stocks on TipRanks >>
BIOL market cap is currently $3.86M and has a P/E ratio of -0.14.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BIOLASE, Inc. is a medical device company, which engages in the development, manufacture, market and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems performs soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Irvine, CA.
Read More on BIOL:
